15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Summit Therapeutics PLC, 7 rate it Buy or better, 5 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $7.70 to $40.00 (about 5.2x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $28.15 sits 124% above the current $12.55. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.21 next quarter toward $-0.91 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy754%
Hold538%
Sell18%
Strong Sell00%
Based on 13 analysts giving stock ratings to Summit Therapeutics PLC.
As of Jul, 7 of 13 firms rate SMMT a Buy (5 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
SMMT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.21
Range $-0.25 – $-0.16 · 8 analysts · -4% YoY
Next period, 8 analysts expect Summit Therapeutics PLC to earn $-0.21 a share (range $-0.25 – $-0.16), versus $-0.21 a year earlier. Full-year consensus is $-0.83, growing to $-0.91 the year after.
REVENUE · NEXT QUARTER
$1.8M
Range $0 – $8.1M · 8 analysts
Revenue is expected to reach $1.8M (range $0 – $8.1M). Full-year consensus is $1.9M, rising to $42.5M next year.
Top analysts covering Summit Therapeutics PLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SMMT.
#1
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$40.00+218.7% to target
Overall win rate
43%
+ Follow
#2
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Hold
No targeton SMMT
Overall win rate
34%
+ Follow
#3
Reni J. Benjamin
JMP Securities · Rank #290
Buy
$40.00+218.7% to target
Overall win rate
33%
+ Follow
#4
Etzer Darout
Barclays
Hold
$18.00+43.4% to target
Coverage
—
+ Follow
#5
DA
Dara Azar
Stifel Nicolaus
Buy
$38.00+202.8% to target
Coverage
—
+ Follow
SMMT stock forecast FAQ
What is SMMT's average 12-month price target?+
The 10 analysts with a live target average $28.15 for Summit Therapeutics PLC over the next 12 months, ranging from a $40.00 high to a $7.70 low.
Is SMMT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 7 are Buy or Strong Buy, 5 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for SMMT?+
The Street-high target is $40.00 (Citizens), and the Street-low is $7.70 (Bernstein). The average of all 10 active targets is $28.15.
How many Wall Street analysts cover SMMT?+
13 analysts have an active rating on Summit Therapeutics PLC, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering SMMT?+
Among analysts who currently cover SMMT, Yigal Nochomovitz of Citigroup has the strongest overall Quantellect track record (Rank #131). Their current call is Buy with a $40.00 target.
What is Summit Therapeutics PLC's projected EPS for next quarter?+
The consensus estimate is $-0.21 per share (range $-0.25 – $-0.16) across 8 analysts. Full-year EPS is projected at $-0.83, rising to $-0.91 the following year.
How much revenue is Summit Therapeutics PLC expected to report next quarter?+
Consensus revenue is $1.8M (range $0 – $8.1M). Full-year revenue is projected at $1.9M, growing to $42.5M next year.
Have analysts been upgrading or downgrading SMMT lately?+
As of Jul, 7 of 13 firms rate SMMT a Buy (5 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SMMT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
